@conference{
author = "Nikolić, Stefan and Arakelyan, Jemma and Kushnarev, Vladimir and Alfadul, Samah Mutasim and Stanković, Dalibor and Kraynik, Yaroslav I. and Babak, Maria V. and Grgurić-Šipka, Sanja",
year = "2023",
abstract = "Ruthenium complexes with dipyrido[3,2-a:2’,3’-c]phenazine (dppz) ligands have been
extensively investigated as potential anticancer agents due to possibility of modulation of their
intracellular accumulation and respective anticancer mechanism of action [1,2]. In recent years
we have explored the anticancer activity of a variety of ruthenium(II)-arene complexes with
dppz based ligands and some of them demonstrated remarkable cytotoxic activity [3].
Following these studies here we present a series of Ru(II)-arene complexes with the general
formula [(η6-arene)Ru(dppz-R)Cl]PF6, where arene fragment was benzene, toluene or pcymene and R was -NO2, -Me or -COOMe with aim to study influence of both of half-sandwich
Ru(II)-arene fragments and the variation of dppz ligands on improvement of the therapeutic
potential of those complexes. All compounds were fully characterized by physico-chemical
methods. The anticancer activity of dppz ligands and respective Ru complexes was assessed
against MDA-MB-231, HCT116 and CT26 cancer cell lines and healthy MRC5 lung
fibroblasts. In vivo efficacy of lead Ru-dppz complex revealed significantly reduction of tumor
burden in mice with colorectal cancers without inducing liver and kidney toxicity. Thus, all the
results indicated that introducing appropriate dppz into ruthenium-arene scaffold was a
promising strategy for developing potent antitumor agents.",
journal = "16th International Symposium on Applied Bioinorganic Chemistry (16-ISABC), Ioannina, Greece, June 11-14, 2023",
title = "New organoruthenium complexes with dipyrido[3,2-a:2’,3’- c]phenazine based ligands",
pages = "130-130",
url = "https://hdl.handle.net/21.15107/rcub_cherry_5958"
}